NASDAQ:LRMR

Larimar Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy LRMR

*Your capital is at risk

$3.81

+0.0900 (+2.42%)

At Close: Jul 15, 2026

Larimar Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 39.16M and sold 0 LRMR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	39.16M shares
● Sell	0 shares
100% Buy Activity Strong Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 06, 2026 Buy	Common Stock P-Purchase	Hamilton Thomas Edward Director	Director	50 000 Value: $166.9K
May 19, 2026 Buy	Stock Option (Right to Buy) A-Award	Hamilton Thomas Edward Director	Director	55 150 Value: $183.6K
May 19, 2026 Buy	Stock Option (Right to Buy) A-Award	Thomas Frank E Director	Director	55 150 Value: $183.6K
May 19, 2026 Buy	Stock Option (Right to Buy) A-Award	Truitt Joseph Director	Director	55 150 Value: $183.6K
May 19, 2026 Buy	Stock Option (Right to Buy) A-Award	Sherman Jeffrey W Director	Director	55 150 Value: $183.6K
May 19, 2026 Buy	Stock Option (Right to Buy) A-Award	Flynn James E * Director By Deputization	Director	55 150 Value: $183.6K
May 19, 2026 Buy	Stock Option (Right to Buy) A-Award	Leff Jonathan S Director	Director	55 150 Value: $183.6K
Feb 27, 2026 Buy	Common Stock P-Purchase	Thomas Frank E Director	Director	5 000 Value: $25.0K
Feb 27, 2026 Buy	Common Stock P-Purchase	Hamilton Thomas Edward Director	Director	100 000 Value: $500.0K
Feb 27, 2026 Buy	Common Stock P-Purchase	Flynn James E * Director By Deputization	Director	2 000 000 Value: $10.0M
Feb 27, 2026 Buy	Common Stock P-Purchase	Flynn James E * Director By Deputization	Director	831 978 Value: $4.16M
Feb 27, 2026 Buy	Common Stock P-Purchase	Flynn James E * Director By Deputization	Director	1 084 010 Value: $5.42M
Feb 27, 2026 Buy	Common Stock P-Purchase	Flynn James E * Director By Deputization	Director	1 084 012 Value: $5.42M
Feb 27, 2026 Buy	Common Stock P-Purchase	Sherman Jeffrey W Director	Director	5 000 Value: $25.0K
Jan 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Clayton Russell Chief Medical Officer	Officer	153 822 Value: $553.8K
Jan 26, 2026 Buy	Common Stock A-Award	Shankar Gopi Chief Development Officer	Officer	25 637 Value: $92.3K
Jan 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Shankar Gopi Chief Development Officer	Officer	153 822 Value: $553.8K
Jan 26, 2026 Buy	Common Stock A-Award	Clayton Russell Chief Medical Officer	Officer	25 637 Value: $92.3K
Jan 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Ben-maimon Carole President And CEO	CEO / President	600 600 Value: $2.16M
Jan 26, 2026 Buy	Common Stock A-Award	Ben-maimon Carole President And CEO	CEO / President	100 100 Value: $360.4K
Jan 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Celano Michael Chief Financial Officer	C-Suite Officer	225 622 Value: $812.2K
Jan 26, 2026 Buy	Common Stock A-Award	Celano Michael Chief Financial Officer	C-Suite Officer	37 604 Value: $135.4K
Jul 31, 2025 Buy	Common Stock P-Purchase	Flynn James E * Director By Deputization	Director	3 387 539 Value: $10.8M
Jul 31, 2025 Buy	Common Stock P-Purchase	Flynn James E * Director By Deputization	Director	3 387 529 Value: $10.8M
Jul 31, 2025 Buy	Common Stock P-Purchase	Flynn James E * Director By Deputization	Director	2 599 932 Value: $8.32M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LARIMAR THERAPEUTICS, INC.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania....

Read Full Profile Here